Skip to main content
Fig. 1 | Trials

Fig. 1

From: Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial

Fig. 1

Overview of study design. Remission = CDAI ≤ 2.8 and ≤ 1/28 swollen joints, LDA = low disease activity = CDAI ≤ 10 but no remission, MDA = moderate disease activity = 10 < CDAI ≤ 22, HDA = high disease activity = CDAI > 22, Pred # = prednisone according to taper schedule, LED = last effective dose

Back to article page

Trials

ISSN: 1745-6215